The end-of-life experience for a cohort of patients with pulmonary arterial hypertension

Daniel C. Grinnan, Keith Mark Swetz, Janet Pinson, Paul Fairman, Laurel J. Lyckholm, Tom Smith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a progressive and ultimately fatal disease of the pulmonary circulation. There has never been an investigation of the end-of-life symptoms in patients with PAH. In this investigation, we surveyed surrogates of recent decedents with PAH. We evaluate their responses to better understand the end-of-life experience of patients with PAH. Methods: The survey instrument includes demographic information and the Edmonton Symptoms Assessment Scale. Accredo Therapeutics mailed the survey to surrogates of recent decedents with PAH, and responses were anonymously returned to investigators at Virginia Commonwealth University and used in our descriptive analysis. Results: Of 100 surveys distributed over 24 months (February 2009 to February 2011), we obtained 36 responses (response rate 36%). We found that most patient deaths (90%) were related to PAH, that the majority of patients died in the hospital (67%), with the majority of in-hospital deaths (83%) occurring in intensive care. Palliative care was infrequently involved in patients' care, and many surrogates were unaware of palliative care and hospice services available to the decedents. Patients died with a high symptom burden, especially dyspnea. Conclusion: In this cohort, patients with PAH usually died from their disease, often in the hospital setting with a high symptom burden. Further study will be needed to confirm the findings from this study and to better understand the forces leading to the trends uncovered in this investigation.

Original languageEnglish (US)
Pages (from-to)1065-1070
Number of pages6
JournalJournal of Palliative Medicine
Volume15
Issue number10
DOIs
StatePublished - Oct 1 2012

Fingerprint

Pulmonary Hypertension
Palliative Care
Hospices
Pulmonary Circulation
Symptom Assessment
Critical Care
Dyspnea
Patient Care
Research Personnel
Demography
Surveys and Questionnaires

ASJC Scopus subject areas

  • Medicine(all)
  • Anesthesiology and Pain Medicine
  • Nursing(all)

Cite this

Grinnan, D. C., Swetz, K. M., Pinson, J., Fairman, P., Lyckholm, L. J., & Smith, T. (2012). The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. Journal of Palliative Medicine, 15(10), 1065-1070. https://doi.org/10.1089/jpm.2012.0085

The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. / Grinnan, Daniel C.; Swetz, Keith Mark; Pinson, Janet; Fairman, Paul; Lyckholm, Laurel J.; Smith, Tom.

In: Journal of Palliative Medicine, Vol. 15, No. 10, 01.10.2012, p. 1065-1070.

Research output: Contribution to journalArticle

Grinnan, DC, Swetz, KM, Pinson, J, Fairman, P, Lyckholm, LJ & Smith, T 2012, 'The end-of-life experience for a cohort of patients with pulmonary arterial hypertension', Journal of Palliative Medicine, vol. 15, no. 10, pp. 1065-1070. https://doi.org/10.1089/jpm.2012.0085
Grinnan, Daniel C. ; Swetz, Keith Mark ; Pinson, Janet ; Fairman, Paul ; Lyckholm, Laurel J. ; Smith, Tom. / The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. In: Journal of Palliative Medicine. 2012 ; Vol. 15, No. 10. pp. 1065-1070.
@article{b40744c9c5e6419999c0c910c3b18fe8,
title = "The end-of-life experience for a cohort of patients with pulmonary arterial hypertension",
abstract = "Introduction: Pulmonary arterial hypertension (PAH) is a progressive and ultimately fatal disease of the pulmonary circulation. There has never been an investigation of the end-of-life symptoms in patients with PAH. In this investigation, we surveyed surrogates of recent decedents with PAH. We evaluate their responses to better understand the end-of-life experience of patients with PAH. Methods: The survey instrument includes demographic information and the Edmonton Symptoms Assessment Scale. Accredo Therapeutics mailed the survey to surrogates of recent decedents with PAH, and responses were anonymously returned to investigators at Virginia Commonwealth University and used in our descriptive analysis. Results: Of 100 surveys distributed over 24 months (February 2009 to February 2011), we obtained 36 responses (response rate 36{\%}). We found that most patient deaths (90{\%}) were related to PAH, that the majority of patients died in the hospital (67{\%}), with the majority of in-hospital deaths (83{\%}) occurring in intensive care. Palliative care was infrequently involved in patients' care, and many surrogates were unaware of palliative care and hospice services available to the decedents. Patients died with a high symptom burden, especially dyspnea. Conclusion: In this cohort, patients with PAH usually died from their disease, often in the hospital setting with a high symptom burden. Further study will be needed to confirm the findings from this study and to better understand the forces leading to the trends uncovered in this investigation.",
author = "Grinnan, {Daniel C.} and Swetz, {Keith Mark} and Janet Pinson and Paul Fairman and Lyckholm, {Laurel J.} and Tom Smith",
year = "2012",
month = "10",
day = "1",
doi = "10.1089/jpm.2012.0085",
language = "English (US)",
volume = "15",
pages = "1065--1070",
journal = "Journal of Palliative Medicine",
issn = "1096-6218",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - The end-of-life experience for a cohort of patients with pulmonary arterial hypertension

AU - Grinnan, Daniel C.

AU - Swetz, Keith Mark

AU - Pinson, Janet

AU - Fairman, Paul

AU - Lyckholm, Laurel J.

AU - Smith, Tom

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Introduction: Pulmonary arterial hypertension (PAH) is a progressive and ultimately fatal disease of the pulmonary circulation. There has never been an investigation of the end-of-life symptoms in patients with PAH. In this investigation, we surveyed surrogates of recent decedents with PAH. We evaluate their responses to better understand the end-of-life experience of patients with PAH. Methods: The survey instrument includes demographic information and the Edmonton Symptoms Assessment Scale. Accredo Therapeutics mailed the survey to surrogates of recent decedents with PAH, and responses were anonymously returned to investigators at Virginia Commonwealth University and used in our descriptive analysis. Results: Of 100 surveys distributed over 24 months (February 2009 to February 2011), we obtained 36 responses (response rate 36%). We found that most patient deaths (90%) were related to PAH, that the majority of patients died in the hospital (67%), with the majority of in-hospital deaths (83%) occurring in intensive care. Palliative care was infrequently involved in patients' care, and many surrogates were unaware of palliative care and hospice services available to the decedents. Patients died with a high symptom burden, especially dyspnea. Conclusion: In this cohort, patients with PAH usually died from their disease, often in the hospital setting with a high symptom burden. Further study will be needed to confirm the findings from this study and to better understand the forces leading to the trends uncovered in this investigation.

AB - Introduction: Pulmonary arterial hypertension (PAH) is a progressive and ultimately fatal disease of the pulmonary circulation. There has never been an investigation of the end-of-life symptoms in patients with PAH. In this investigation, we surveyed surrogates of recent decedents with PAH. We evaluate their responses to better understand the end-of-life experience of patients with PAH. Methods: The survey instrument includes demographic information and the Edmonton Symptoms Assessment Scale. Accredo Therapeutics mailed the survey to surrogates of recent decedents with PAH, and responses were anonymously returned to investigators at Virginia Commonwealth University and used in our descriptive analysis. Results: Of 100 surveys distributed over 24 months (February 2009 to February 2011), we obtained 36 responses (response rate 36%). We found that most patient deaths (90%) were related to PAH, that the majority of patients died in the hospital (67%), with the majority of in-hospital deaths (83%) occurring in intensive care. Palliative care was infrequently involved in patients' care, and many surrogates were unaware of palliative care and hospice services available to the decedents. Patients died with a high symptom burden, especially dyspnea. Conclusion: In this cohort, patients with PAH usually died from their disease, often in the hospital setting with a high symptom burden. Further study will be needed to confirm the findings from this study and to better understand the forces leading to the trends uncovered in this investigation.

UR - http://www.scopus.com/inward/record.url?scp=84866123796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866123796&partnerID=8YFLogxK

U2 - 10.1089/jpm.2012.0085

DO - 10.1089/jpm.2012.0085

M3 - Article

C2 - 22845004

AN - SCOPUS:84866123796

VL - 15

SP - 1065

EP - 1070

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

SN - 1096-6218

IS - 10

ER -